Clinical Trial Update: ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing panitumumab to cetuximab in KRAS wild-type metastatic colorectal cancer has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• Panitumumab (panitumumab)

Snippet

Sponsor: Amgen | Conditions: Metastatic Colorectal Cancer | Phase 3 | Status: COMPLETED | Results posted: 2014-03-24